Current Opinion in Oncology最新文献_第2页

Biomarkers in advanced renal cell carcinoma: current practice and future directions. 晚期肾细胞癌的生物标志物：目前的实践和未来的方向。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-03-27 DOI: 10.1097/CCO.0000000000001138

Vivian Wong, Taylor Goodstein, Gabriela Bravo Montenegro, Ramaprasad Srinivasan, Eric A Singer

{"title":"Biomarkers in advanced renal cell carcinoma: current practice and future directions.","authors":"Vivian Wong, Taylor Goodstein, Gabriela Bravo Montenegro, Ramaprasad Srinivasan, Eric A Singer","doi":"10.1097/CCO.0000000000001138","DOIUrl":"10.1097/CCO.0000000000001138","url":null,"abstract":"Purpose of review: This review focuses on contemporary research into potential prognostic and therapeutic biomarkers for advanced renal cell carcinoma (RCC) published over the past 18 months. Beyond serum lab values, there is no consensus on the use of specific biomarkers for this purpose. Potential biomarkers being investigated consist of genetic, protein, immunologic, and radiologic candidates.Recent findings: New insights in genomic biomarkers include a better understanding of VHL mutational heterogeneity, tumor mutational burden, and the importance of genes like PBRM1 and SETD2 . Protein biomarkers such as C-reactive protein (CRP) and PDZK1 have demonstrated utility in predicting disease progression, therapeutic response, and survival, while immunologic biomarkers like PSMD2, cytokines, and Tregs continue to shed light on the tumor microenvironment and immune evasion. Emerging imaging biomarkers, from CAIX-targeted radiotracers to PSMA-based PET-CT, offer noninvasive diagnostic and prognostic tools that may revolutionize RCC management.Summary: There are several promising biomarkers currently under investigation for use in advanced RCC.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"274-282"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel therapeutics in refractory germ cell tumors. 难治性生殖细胞肿瘤的新疗法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-18 DOI: 10.1097/CCO.0000000000001129

Noah H Richardson, Nabil Adra

{"title":"Novel therapeutics in refractory germ cell tumors.","authors":"Noah H Richardson, Nabil Adra","doi":"10.1097/CCO.0000000000001129","DOIUrl":"10.1097/CCO.0000000000001129","url":null,"abstract":"Purpose of review: Refractory germ cell tumors (GCT), those progressing after known effective salvage therapies, carry a dismal prognosis with minimal treatment options of limited efficacy. This review aims to highlight the advances in understanding refractory GCT and review upcoming and active clinical trials with novel therapeutics in development.Recent findings: Patients with refractory disease after optimal salvage chemotherapy are rarely cured and should be referred to centers with expertise in GCT. While prior investigational agents have not overcome current limitations of salvage therapy, current and upcoming trials of novel agents including tyrosine kinase inhibitors (TKI), chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell engagers (BiTE), and antibody-drug conjugates (ADC) are promising avenues of therapy.Summary: Outcomes in refractory GCT remain poor. Patients should preferably be evaluated at tertiary care centers with expertise in the management of these patients and access to clinical trials of novel therapeutics. Active research in the understanding of the molecular mechanisms of resistance and targeting of uniquely expressed antigens has broadened the potential therapies in development.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"267-273"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma. 复发性或转移性头颈部鳞状细胞癌的治疗前景。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-03-06 DOI: 10.1097/CCO.0000000000001133

Thibault Gauduchon, Eve Marie Neidhardt, Jerome Fayette

{"title":"Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma.","authors":"Thibault Gauduchon, Eve Marie Neidhardt, Jerome Fayette","doi":"10.1097/CCO.0000000000001133","DOIUrl":"10.1097/CCO.0000000000001133","url":null,"abstract":"Purpose of review: Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains a significant therapeutic challenge due to its biological complexity and clinical heterogeneity. This review addresses the relevance of exploring novel therapeutic approaches, particularly in light of recent advances and the persistent unmet needs in patient outcomes.Recent findings: Recent phase II and III clinical trials have highlighted promising strategies, including combinations of immunotherapy with targeted therapies, antibody-drug conjugates (ADCs), HPV vaccines, dual immunotherapy approaches, and therapies targeting the tumor microenvironment. These innovations represent emerging directions to overcome resistance mechanisms and improve treatment efficacy.Summary: The findings suggest that integrating innovative strategies such as ADCs, immunotherapy combinations, and tumor microenvironment-targeting therapies may significantly enhance clinical outcomes for patients with R/M HNSCC. Further research is essential to refine these approaches and optimize their application in clinical practice.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"175-183"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation of the 2024 ASCO guidelines for the prevention and management of osteoradionecrosis in patients with head & neck cancer treated with radiation therapy. 2024 ASCO头颈癌放疗患者放射性骨坏死的预防和管理指南。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-19 DOI: 10.1097/CCO.0000000000001130

Douglas E Peterson, Noam Yarom, Charlotte Duch Lynggaard, Nofisat Ismaila, Deborah Saunders

{"title":"Implementation of the 2024 ASCO guidelines for the prevention and management of osteoradionecrosis in patients with head & neck cancer treated with radiation therapy.","authors":"Douglas E Peterson, Noam Yarom, Charlotte Duch Lynggaard, Nofisat Ismaila, Deborah Saunders","doi":"10.1097/CCO.0000000000001130","DOIUrl":"10.1097/CCO.0000000000001130","url":null,"abstract":"Purpose of review: Osteoradionecrosis may often be prevented in context of interprofessional healthcare that includes dental specialists prior to and following completion of the patient's head and neck radiation therapy. Important factors, however, compromise delivery of guideline-concordant management of osteoradionecrosis (ORN), including patient access to this interprofessional care. This review is directed to these and related issues, in order to foster enhanced approaches for ORN management.Recent findings: The review is centered in the 2024 Journal of Clinical Oncology publication 'Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline', and the companion 2024 JCO Oncology Practice publication in which clinical insights for the guideline are addressed. Key recent literature is cited in order to provide contemporary context to clinical decision-making for prevention and early diagnosis and treatment of ORN. Although a relatively infrequent complication in head and neck radiation patients, ORN can have profound clinical and financial impact when it occurs.Summary: Interprofessional oncology care is essential for ORN management. Future research is needed in order to enhance this management, including studies directed to predicting risk of development of ORN based on patient-centered risk factors.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"184-193"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? 新辅助免疫治疗黑色素瘤：病理反应作为替代终点？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-27 DOI: 10.1097/CCO.0000000000001119

Michel Meyers, Oumnia Mouna, Mireille Langouo

{"title":"Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?","authors":"Michel Meyers, Oumnia Mouna, Mireille Langouo","doi":"10.1097/CCO.0000000000001119","DOIUrl":"10.1097/CCO.0000000000001119","url":null,"abstract":"Purpose of review: This review evaluates by analyzing recent studies whether pathological complete response (pCR) can be used as a reliable surrogate marker for overall survival (OS) in melanoma treated with neoadjuvant immunotherapy.Recent findings: Trials like Neo-Combi, Neo-Trio and COMBI-Neo show that pCR is crucial for long-term success in targeted therapy for melanoma, while studies like OpACIN-neo and SWOG S1801 demonstrate that immunotherapy can provide durable benefits even with partial responses. Findings from NADINA and the INMC analysis highlight that immunotherapy achieves higher pathologic response rates and improved survival outcomes, offering broader benefits compared to the pCR-dependent outcomes of targeted therapy.Summary: pCR serves as a critical prognostic biomarker across cancer types, with strong validation in breast cancer where it predicts long-term survival, particularly in aggressive subtypes like triple-negative and HER2-positive breast cancer. In melanoma, pCR is gaining prominence as a surrogate marker in neoadjuvant therapies, with its predictive value varying between targeted treatments - where achieving pCR is essential - and immunotherapies, which provide durable survival benefits even with partial responses. Despite its potential, the role of pCR as a universally reliable surrogate endpoint in melanoma requires further validation through cancer-specific studies to ensure accurate treatment guidance and personalized care.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"116-120"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can febrile neutropenia re-invent its self? 发热性中性粒细胞减少症能自我改造吗？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1097/CCO.0000000000001116

Aspasia Georgala, Jean Klastersky

{"title":"Can febrile neutropenia re-invent its self?","authors":"Aspasia Georgala, Jean Klastersky","doi":"10.1097/CCO.0000000000001116","DOIUrl":"10.1097/CCO.0000000000001116","url":null,"abstract":"Purpose of review: Febrile neutropenia as a complication of cytotoxic chemotherapies, remains a major event in the medical journey of hematology and oncology patients. In this review, we are trying to review the new elements and highlights that are shaping febrile neutropenia in nowadays.Recent findings: Introduction of risk-stratification, expanded use of granulocyte-colony stimulating factor and oral treatment for selected patients and rapid administration of antibiotics revolutionized the treatment of febrile neutropenia. Oral treatment with moxifloxacine or amoxicillin-clavulanate + ciprofloxacin has already been widely tested and is actually a standard of care for a meticulously selected group of patients managed as ambulatory patients. Intravenous treatment of febrile neutropenia is a major challenge for clinicians and microbiologists since the blast of the \"silent pandemic\" of antimicrobial resistance.Summary: In this setting, strategies that reduce the chances of febrile neutropenia, misuse of antibiotics and enhance the rigorous control of infections may offer a chance to improve the management of febrile neutropenia and offer to our patients the chance to continue their antineoplastic treatment without perturbations.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"163-167"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immuno-oncology in the daily practice. 免疫肿瘤学的日常实践。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-27 DOI: 10.1097/CCO.0000000000001117

Ariane Laparra

{"title":"Immuno-oncology in the daily practice.","authors":"Ariane Laparra","doi":"10.1097/CCO.0000000000001117","DOIUrl":"10.1097/CCO.0000000000001117","url":null,"abstract":"Purpose of review: Immune checkpoint inhibitors (ICI) have become an integral part of oncology treatment. ICI currently has approval for more than thirty tumor types with proven efficacy. However, ICI can expose patients to inflammatory side effects, such as immuno-related adverse events (irAE). The spectrum of irAE and the time to onset can be very broad, sometimes leading to the patient's death.Additionally, ICI could be associated with chronic or long-term adverse events that impact quality of life. The expansion of the indications for immunotherapy in the early adjuvant and neoadjuvant stages is altering the benefit-risk balance of these therapies.Furthermore, the combination of immunotherapies with other oncology treatments makes the interpretation of adverse events difficult.To date, no predictive factors have been identified in routine practice to identify patients at risk of developing serious toxicity.Recent findings: This has led us to develop a patient care pathway dedicated to the management of these toxicities, enabling early detection of irAE to improve outcomes.Summary: We have presented a novel care pathway based on a clinical evaluation, encompassing a daily hospital devoted to the management of toxicities, an iTox multidisciplinary board, and a pharmacovigilance database. This pathway involves a translational research program.The toxicity day hospital allowed us to care for patients at an early stage of an adverse event and to establish whether anticancer treatment was responsible for the onset of symptoms and/or biological abnormalities.The objective of this pathway is to enhance the quality of life and compliance of oncology treatment, while minimizing the necessity for unscheduled care.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"136-141"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. 自从辅助治疗被批准以来，III期黑色素瘤是否还有淋巴结清扫的余地？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-15 DOI: 10.1097/CCO.0000000000001118

Oumnia Mouna, Charlotte Hanssens, Michel Meyers, Mireille Langouo

{"title":"Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.","authors":"Oumnia Mouna, Charlotte Hanssens, Michel Meyers, Mireille Langouo","doi":"10.1097/CCO.0000000000001118","DOIUrl":"10.1097/CCO.0000000000001118","url":null,"abstract":"Purpose of review: This review aims to explore the evolving management strategies for stage III melanoma, focusing on the comparative effectiveness of traditional surgical approaches like complete lymph node dissection (CLND) versus modern adjuvant therapies. It also examines the latest evidence on the efficacy, risks, and complications of these strategies, emphasizing the role of shared decision-making between patients and clinicians.Recent findings: Recent clinical trials and meta-analyses, including the MSLT-II and DeCOG-SLT studies, have demonstrated that CLND may not significantly improve survival outcomes in melanoma patients with sentinel lymph node biopsy (SLNB)-positive status. Instead, a shift towards observation combined with adjuvant therapies such as immune checkpoint inhibitors and targeted therapies (for BRAF-mutant melanoma) has been observed. These approaches have been associated with similar or improved recurrence-free survival rates and reduced treatment-related complications. However, challenges remain in establishing standardized protocols for adjuvant therapy use.Summary: The management of stage III melanoma is rapidly transitioning from routine CLND towards a more individualized approach that incorporates active surveillance and adjuvant therapies based on tumor biology and patient-specific factors. Multidisciplinary discussions are essential to guide treatment decisions, and further research is required to develop clear, evidence-based protocols.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"110-115"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to monitor the side effects of treatments in cancer patients. 如何监测癌症患者治疗的副作用。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2025-01-03 DOI: 10.1097/CCO.0000000000001123

Mario Di Palma

引用次数: 0

From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma. 从基础到临床和治疗见解：光化性角化病和皮肤鳞状细胞癌的新闻。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-03-01 Epub Date: 2024-12-23 DOI: 10.1097/CCO.0000000000001115

Carmen Orte Cano, Mariano Suppa, Ievgenia Pastushenko, Véronique Del Marmol

{"title":"From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma.","authors":"Carmen Orte Cano, Mariano Suppa, Ievgenia Pastushenko, Véronique Del Marmol","doi":"10.1097/CCO.0000000000001115","DOIUrl":"10.1097/CCO.0000000000001115","url":null,"abstract":"Purpose of review: Squamous cell carcinoma (SCC) is the second most common skin cancer, with an increasing incidence. This review highlights this past year's advances regarding the understanding of its pathogenesis, newly introduced diagnostic methods and updates in prevention and treatment.Recent findings: While the pathogenesis of SCC progression remains unclear, new sequencing techniques are helping to better characterize these tumours at the molecular level. Recently introduced noninvasive imaging techniques are rapidly transforming SCC diagnosis and follow-up. Although nicotinamide has not demonstrated significant benefit in reducing SCC incidence among transplant recipients, larger studies are needed to achieve statistical power. Tirbanibulin, a new field treatment for actinic keratosis is now available and well tolerated for use in areas up to 100 cm 2 . Surgery remains the cornerstone of SCC treatment and can now be complemented with cemiplimab, when advanced.Summary: Recent years have seen a diagnostic revolution in dermatology, driven by noninvasive imaging and artificial intelligence; however, the physiopathogenesis of SCC progression remains poorly understood. In treatment, immune checkpoint inhibitors have shown good survival outcomes for advanced SCC. Research continues in the neoadjuvant setting and among transplanted patients, with encouraging preliminary results.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"105-109"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0